WO2006036082A1 - Produit cosmetique et procede de fabrication correspondant - Google Patents

Produit cosmetique et procede de fabrication correspondant Download PDF

Info

Publication number
WO2006036082A1
WO2006036082A1 PCT/RU2004/000347 RU2004000347W WO2006036082A1 WO 2006036082 A1 WO2006036082 A1 WO 2006036082A1 RU 2004000347 W RU2004000347 W RU 2004000347W WO 2006036082 A1 WO2006036082 A1 WO 2006036082A1
Authority
WO
WIPO (PCT)
Prior art keywords
peptide
telomeric
dna
sequence
complex
Prior art date
Application number
PCT/RU2004/000347
Other languages
English (en)
Russian (ru)
Inventor
Artur Vladimirovich Rybakin
Original Assignee
Obschestvo S Ogranichennoy Otvetstvennostyu 'sankt-Peterburgsky Institut Krasoty'
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Obschestvo S Ogranichennoy Otvetstvennostyu 'sankt-Peterburgsky Institut Krasoty' filed Critical Obschestvo S Ogranichennoy Otvetstvennostyu 'sankt-Peterburgsky Institut Krasoty'
Priority to PCT/RU2004/000347 priority Critical patent/WO2006036082A1/fr
Publication of WO2006036082A1 publication Critical patent/WO2006036082A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/606—Nucleosides; Nucleotides; Nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Definitions

  • the present invention relates to the field of cosmetology and relates to skin care products.
  • cosmetics are known to enhance the appearance of the skin.
  • cosmetics are known, the use of which allows you to accumulate and retain water in the skin, thereby eliminating or preventing dryness and loss of skin elasticity for some time.
  • antioxidants that bind free radicals formed in the skin or prevent the formation of new ones, thereby preventing the occurrence of reactions with their participation that adversely affect the normal functioning of the cell.
  • drugs are known that contain ascorbic acid or vitamin E as antioxidants (Holsk David E. E., Jon D. Na, Fasial skip reptiviop, Cyr Orip and Orthal 14: 249).
  • Known cosmetics containing substances include ascorbic acid or vitamin E as antioxidants (Holsk David E. E., Jon D. Na, Fasial skip reptiviop, Cyr Orip and Orthal 14: 249).
  • retinoids e.g. retinoids (Nolsk David EE, Joh D. D. ⁇ / q, Facial skip diet, Hypalpol 14: 248), which stimulate fibroblast activity and the synthesis of new collagen fibers in the dermis, as well as mitotic activity and cell renewal, leading to a decrease in the thickness of the stratum corneum, an increase in the thickness of the granular layer of the skin and an improvement in the structure of the skin.
  • retinoids Nolsk David EE, Joh D. D. ⁇ / q, Facial skip diet, Hypalpol 14: 248
  • a disadvantage of the known cosmetics is that they do not affect the aging process of the skin cells of the body, giving only a relatively small effect on improving its functions and appearance. Disclosure of invention
  • An object of the present invention is to provide a cosmetic product capable of preventing aging of skin cells, thereby improving skin function and appearance more effectively.
  • the proposed cosmetic product containing the active ingredient and the carrier in which, according to the invention, the active ingredient contains a complex that includes a telomeric DNA sequence and its associated peptide having a nuclear localization signal (NLS), and which is able to penetrate across the plasma membrane of the cell.
  • NLS nuclear localization signal
  • the telomeric DNA sequence contained in it penetrates the nucleus of the skin cell, leading to an increase in the number of divisions that the cell is able to carry out, i.e. slowing down the aging process of the cell, as a result of which the skin acquires a large number of young cells.
  • This ensures the acceleration of re-epithelialization of the skin, an increase in the density of its cells and counteraction to thinning of the skin in the epidermis, as well as an increase in the production of elastin fibers by fibroblasts in the dermis.
  • the result is a more effective improvement in the appearance of the skin, as well as its more efficient functioning.
  • said peptide contained in a cosmetic product of the invention may include a protein transduction domain (PTD).
  • PTD protein transduction domain
  • Such peptides may contain the amino acid sequences GRKKRRQRRRPPQKKKKKKV, RQIKIWFQNRRKKKKKKKKKKK OR
  • the indicated ability to penetrate the plasma membrane of a cell can also be achieved by using a complex including a liposome into which the indicated telomeric DNA sequence and the indicated peptide are introduced.
  • This problem is also solved by the fact that the proposed method of obtaining a cosmetic product, including the synthesis of the telomeric sequence of human DNA and the connection of the obtained telomeric sequence with a peptide having a nuclear localization signal, with the formation of a complex that can penetrate through the plasma membrane of the cell.
  • a peptide containing a protein transduction domain can be used.
  • the telomeric DNA sequence and the peptide associated with it are introduced into the liposome.
  • the telomeric sequence is synthesized based on the total genomic DNA used as a matrix, which is obtained from a blood sample or human tissue to which the cosmetic product is intended to be applied.
  • the proposed cosmetic product contains the active ingredient and a carrier.
  • the active ingredient is a complex that includes a telomeric DNA sequence and is able to penetrate the plasma membrane of the cell.
  • the complex also contains a peptide linked to a telomeric sequence b having a nuclear localization signal.
  • Telomeric regions, or telomeres, of DNA chromosomes are special terminal regions of linear chromosomal DNA, to which certain proteins are also associated. It is believed that telomeres, in particular, protect chromosomes from degradation and fusion with other chromosomes.
  • Telomeric DNA consists of repeatedly repeated short tandem nucleotide sequences, where one DNA strand is enriched in guanine (G), and its complementary strand is enriched in cytidine (C). In humans, like most eukaryotes, G-rich the telomeric DNA chain is constructed from TTAGGG blocks, and the C-rich chain contains CCCTAA blocks.
  • the proposed cosmetic product preferably includes telomeric sequences of human DNA containing from 100 to 300 p. However, sequences of a different length can also be used according to the present invention.
  • a nuclear localization signal refers to an amino acid sequence, also called NLS (from the English expression “nuclear losalysis sequence”), recognized by certain receptors on the cell’s nuclear membranes that carry the peptide containing it from the cytoplasm into the nucleus.
  • NLS sequences are described, for example, in Japs D. A. et al., Nisleart tarapetipa resorpShop: And kev soptrol poipt and postpaprrt? 2000, BioEssavs 22: 532-544.
  • NLS sequences include, in particular, the NLS sequence of the T-antigen (T-ant) of the SV-40 virus, consisting of PKKKRKV amino acids, which are recognized and associated with a number of receptors of the nuclear membranes of human cells involved in the transport of peptides into the nucleus, and some similar with it amino acid sequences.
  • T-ant T-antigen
  • PKKKRKV amino acids which are recognized and associated with a number of receptors of the nuclear membranes of human cells involved in the transport of peptides into the nucleus, and some similar with it amino acid sequences.
  • the peptides that make up this complex may contain other amino acid sequences.
  • Obtaining a complex capable of penetrating through the plasma membrane of a cell can be achieved by including in it any components giving this property.
  • protein sequences also known as PTDs (from the expression “protein truncation domain”), or “penetrating into the cell of the peptides. " The protein transduction domain gives peptides having such domains the ability to penetrate the plasma membrane of cells.
  • PTD amino acid sequences are known (see, for example, Kaboyridis PS, Biodisal arrlisatiop of prototype tripsol, TRENDS ip Biolav, vol. 21, No.11, Novetber 2003, 498-503).
  • HCV human immunodeficiency virus
  • PTD sequence is a peptide corresponding to amino acids 43-58 of the protein of the Antennapedia family of homeoboxic proteins (Apt), found in Dsorchil, and having the amino acid sequence RQIK1WFQNRRMKWKK
  • PTD amino acid sequences can be included in a peptide linked to a telomeric sequence and carrying NLS.
  • peptides that can be used in the complex contained in the cosmetic product of the invention are, for example,
  • GRKKRRQRRRPPQKKKKRKV which is a fusion protein containing PTD, which is a 13-amino acid sequence of TAT (48-60), and NLS, which is a sequence of 7 amino acids T-ag SV-40.
  • Another peptide that can be used to create this complex is RQIKIWFQNRRMKWKKKKKKRKV, which is a fusion protein containing 16-amino acid PTD Aptr (43-58) and 7-amino acid NLS T-ag SV-40.
  • MPG is a 27-amino acid peptide GALFLGFLGAAGGTMTGGWSQ ⁇ S ⁇ V, CONSIDERING OF HYDROPHOBIC
  • PTD domain which is the sequence of HIV-1 gp41, (amino acids 1-16), and the hydrophilic domain (amino acids 20-27), which is T-ag SV-40 (see also Morris MC, Chalip L Merv J Heitz. F apd Divita G. And then I finished the song strateav fore delivep / sipa and sipale reptide sargier, 1999. Nislés As Res. 27. 3510-3517).
  • telomeric sequences with a peptide in a complex contained in a cosmetic product according to the invention can be of a different nature.
  • Peptides containing NLS and PTD carry a positive charge and can directly bind to negatively charged DNA.
  • Chemical bonds between telomeric DNA and peptides can be formed with the participation of chemical groups both already present in these molecules and introduced into them by known modifications, for example, using the biotin-streptavidin system.
  • Other substances besides PTD can be used to allow the complex of the invention to enter the cell.
  • the complex of telomeric DNA and peptide having NLS contained in the cosmetic product of the invention further includes a liposome into which said telomeric DNA and said peptide are introduced.
  • Liposomes are vesicles having membranes that consist of lipid bilayers, mainly phospholipids, and which contain an internal aqueous phase. Liposomes are widely used in medicine and cosmetology to deliver the substances enclosed in them into cells.
  • a cosmetic product according to the invention may contain both single and multi-layer liposomes.
  • Liposomes useful in such a cosmetic product may contain traditional ingredients. So, lipids are mainly phospholipids and their derivatives. Commonly used lipids include, in particular, phosphatidylcholine, cholesterol, phosphatidylethanolamine, dioleylphosphatidylglycerol, dioleylphosphatidylethanolamine and others.
  • aqueous phase in the liposomes contained in the cosmetic product according to the invention in addition to the telomeric DNA bound peptides, can also contain auxiliary ingredients traditional for liposomes, for example buffers, antioxidants (for example sodium ascorbate) and chelating agents (for example ethylenediaminetetraacetic acid).
  • auxiliary ingredients traditional for liposomes for example buffers, antioxidants (for example sodium ascorbate) and chelating agents (for example ethylenediaminetetraacetic acid).
  • Carriers that can be used as part of the proposed cosmetic products are buffers, bases for ointments and creams, and other traditional carriers for cosmetic preparations. Carriers may contain buffering agents, gelling agents, preservatives, and other excipients used in the art.
  • the proposed method of obtaining a cosmetic product includes the synthesis of a telomeric sequence of human DNA and the connection of the obtained telomeric DNA sequence with a peptide having a nuclear localization signal, with the formation of a complex that can penetrate through the plasma membrane of the cell.
  • the telomeric sequence of human DNA can be obtained and amplified by polymerase chain reaction (PCR) using total genomic DNA isolated from human body tissues as a seed. For example, it is convenient to obtain DNA from human blood cells. Total genomic DNA is isolated from human tissue, in particular from blood leukocytes, by known methods, for example, by phenol-chloroform extraction. Selection of conditions for PCR is a routine procedure and is carried out by known methods. To generate telomeric DNA, the PCR product can be amplified again. From a pool of telomeric sequences obtained in PCR of different lengths, sequences of the desired length are isolated, for example, by gel electrophoresis followed by extraction DNA from the gel, while the selection of conditions for such isolation is also a routine for specialists.
  • PCR polymerase chain reaction
  • Cloning in plasmids can also be used to generate additional numbers of telomeric DNA sequences and their storage.
  • Suitable plasmids include, for example, pCR 2.1. Cloning is conveniently performed using the TA-cloning kit (IPvitrodep).
  • Peptides containing NLS as well as peptides containing both NLS and PTD, for example, as described above, can be obtained, for example, by chemical synthesis.
  • telomeric DNA sequences with a peptide having NLS is carried out, for example, by introducing both components into a carrier, which is a buffer solution having a pH close to 7.0.
  • a carrier which is a buffer solution having a pH close to 7.0.
  • the preferred molar ratio of the peptide to telomeric sequences is 100: 1 and higher.
  • Electrophoresis in a 1% agarose gel followed by staining with ethidium bromide and UV light photography allows detection of a delay in the migration of DNA fragments in the gel, which indicates the formation of the complex.
  • the telomeric DNA sequence and peptide can be introduced into the liposome.
  • liposomes containing DNA associated with the peptide are carried out according to standard methods. Liposomes containing these active substances are obtained, for example, by dispersing lipids and DNA / peptide complexes in an aqueous medium, followed by mechanical stirring, sonication and / or extrusion through filters with a defined pore size. Liposomes can also be obtained by solubilization of lipids and active substances in organic solvents or detergents, mixing with an aqueous medium and subsequent removal of the solvent, as well as other known methods.
  • Example 1 Example 1
  • Total DNA was isolated from human blood leukocytes (0.5 ml whole blood) using the standard phenol-chloroform extraction method. The DNA yield after extraction was 40-50 ⁇ g.
  • Amplification of DNA repeats' telomere was performed by polymerase chain reaction (PCR) which is carried out in a 30 .mu.l reaction mixture containing 67 mM Tris-HCL (pH 8.8), 16.6 mM (NH4) 2SO4, 0.1% Tritop X-100, 2.0mM MgCI_2, 0.5% dimethyl sulfoxide (DMSO), 4% formamide, 3 ⁇ l 25 mM dNTP, 3 units of Taq DNA polymerase, 2 ⁇ g of isolated genomic DNA, 30 pmol of direct (Forward) primer (TTAGGG) 5 , 20 pmol of reverse (Reverse) , (AATCCC) 5 .
  • PCR polymerase chain reaction
  • Both primers were obtained according to the technique proposed by Lorite et al., J. of Finalit 2002: 93 (4).
  • PCR was performed on a thermocycler using a hot stagt. After initial denaturation at 94 ° C for 3 min with the Forward primer, Taq polymerase was introduced and incubated for an additional 7 min at the same temperature. Then, 10 amplification cycles were performed in the following mode: melting at 94 ° C for 1 min, annealing at 70 ° C for 1 min, synthesis of 72 ° C for 1 min. After completion of 10 cycles, a pause of 9O 0 C was established for 10 minutes, the Reverse primer was introduced. Then, 35 cycles of amplification were carried out in the same temperature-time regime as for the previous 10 cycles. After completing 35 amplification cycles, the final synthesis was performed at 72 ° C for 7 min.
  • Detection of the DNA-peptide complex was carried out by electrophoresis on a 1% agarose gel by staining with ethidium bromide and subsequent exposure to UV light. The delay (retardation) of migration of the DNA fragment in the gel indicated the formation of the complex.
  • the use of cosmetics can be carried out in various ways.
  • the specified cosmetic product can be presented, for example, in the form of creams, ointments, gels, etc., intended for application to the skin, or solutions intended both for application to the skin (for example, using patches), and for subcutaneous administration useful for acting on dermal cells, for example fibroblasts. It is known that normal human somatic cells are able to divide only a limited number of times (the so-called
  • Heiflik limit It has been proven that with each division of the somatic cell, as a result of the so-called “end-non-replication” problem, the length of telomeric DNA is reduced (Greider S. M., 1996, Appial Rev. Bioshet., 65, 337-365); when the telomere is shortened to a certain length, the cell ceases to divide, turning into a state senility, or senesensa, after which it ceases to function normally and dies.
  • telomeric DNA and the peptide associated with it penetrate into the cells due to the presence in the peptide of a component, such as PTD, which gives the complex containing DNA and peptide the ability to penetrate the cell membrane, or due to the liposome into which the DNA is introduced and a peptide and which is capable of transporting its contents across the cell membrane.
  • a component such as PTD
  • PTD protein peptide
  • the presence of a nuclear localization signal in the peptide allows the peptide-telomeric DNA complex to penetrate through the nuclear membrane into the cell nucleus.
  • the telomere DNA sequence Penetrated into the nucleus of the cell, the telomere DNA sequence, using the enzyme systems present in the cell, attaches to the ends of the chromosomes, attaching them.
  • the cell “rejuvenates”, i.e. becomes able to carry out more divisions.
  • the skin into which the cosmetic is introduced produces more young cells.
  • the epidermal re-epithelialization process is accelerated, which provides the skin surface with younger and denser cells.
  • the epidermis is effectively maintained.
  • the penetration of the telomeric DNA-peptide complex contained in the cosmetic product into the fibroblasts located in the dermis ensures the production of more young fibroblasts in it, which, unlike the old ones, produce more elastin fibers, which makes the skin more elastic.
  • Providing the skin surface with young and densely spaced cells, maintaining the thickness of the epidermis and increasing skin elasticity provide an effective improvement in the functions and appearance of the skin.
  • the transportation of the telomeric DNA sequence into a cell carried out using the proposed cosmetic product avoids undesirable ' immunological reactions, toxic response and possible mutations.
  • This invention can be used in various skin care products used in cosmetology to improve the appearance of human skin.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne un produit cosmétique destiné à améliorer l'aspect de la peau et comprenant un ingrédient actif ainsi qu'un excipient, l'ingrédient actif comprenant un complexe qui inclut une séquence télomérique d'ADN et un peptide qui y est lié, ce dernier comportant un signal de localisation nucléaire et étant capable de traverser la membrane plasmatique de la cellule.
PCT/RU2004/000347 2004-09-06 2004-09-06 Produit cosmetique et procede de fabrication correspondant WO2006036082A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/RU2004/000347 WO2006036082A1 (fr) 2004-09-06 2004-09-06 Produit cosmetique et procede de fabrication correspondant

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/RU2004/000347 WO2006036082A1 (fr) 2004-09-06 2004-09-06 Produit cosmetique et procede de fabrication correspondant

Publications (1)

Publication Number Publication Date
WO2006036082A1 true WO2006036082A1 (fr) 2006-04-06

Family

ID=36119167

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU2004/000347 WO2006036082A1 (fr) 2004-09-06 2004-09-06 Produit cosmetique et procede de fabrication correspondant

Country Status (1)

Country Link
WO (1) WO2006036082A1 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194253A (en) * 1988-09-09 1993-03-16 Pier Auge (Societe Anonyme) Aqueous gel, usable in cosmetics, based on hyaluronic acid and deoxyribonucleic acid, and a preparation process
US5547684A (en) * 1993-02-10 1996-08-20 Pharmec Company Cosmetic composition containing a DNA-sodium salt and methods of making and using the same
RU2117474C1 (ru) * 1995-02-23 1998-08-20 Закрытое акционерное общество "Фаркавер" Липосомный фармацевтический препарат и лечебно-профилактический крем на его основе
US6372717B1 (en) * 1996-08-23 2002-04-16 Sederma S.A. Synthetic peptides and their use in cosmetic or dermopharmaceutical compositions
FR2849376A1 (fr) * 2002-12-30 2004-07-02 Jean Noel Thorel Composition cosmetique comprenant un complexe actif constitue d'au moins un peptide ou une proteine et au moins un nucleotide, polynucleotide ou acide nucleique
FR2849377A1 (fr) * 2002-12-30 2004-07-02 Jean Noel Thorel Composition cosmetique, regulatrice de la flore cutanee

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194253A (en) * 1988-09-09 1993-03-16 Pier Auge (Societe Anonyme) Aqueous gel, usable in cosmetics, based on hyaluronic acid and deoxyribonucleic acid, and a preparation process
US5547684A (en) * 1993-02-10 1996-08-20 Pharmec Company Cosmetic composition containing a DNA-sodium salt and methods of making and using the same
RU2117474C1 (ru) * 1995-02-23 1998-08-20 Закрытое акционерное общество "Фаркавер" Липосомный фармацевтический препарат и лечебно-профилактический крем на его основе
US6372717B1 (en) * 1996-08-23 2002-04-16 Sederma S.A. Synthetic peptides and their use in cosmetic or dermopharmaceutical compositions
FR2849376A1 (fr) * 2002-12-30 2004-07-02 Jean Noel Thorel Composition cosmetique comprenant un complexe actif constitue d'au moins un peptide ou une proteine et au moins un nucleotide, polynucleotide ou acide nucleique
FR2849377A1 (fr) * 2002-12-30 2004-07-02 Jean Noel Thorel Composition cosmetique, regulatrice de la flore cutanee

Similar Documents

Publication Publication Date Title
EP0581848B1 (fr) Oligonucleotides fermes, antisens et sens, et leurs applications
JP2022501367A (ja) 脂質ナノ粒子の調製及びその投与方法
KR20210135494A (ko) 지질 나노입자의 제조 방법
JP7027303B2 (ja) メラニン産生を抑制するｒｎａ複合体
KR20220133957A (ko) 지질 나노입자의 제조 방법
US20130324586A1 (en) Inhibition of Hairless Protein mRNA
US20060270621A1 (en) Inhibition of hair growth with RNAi targeting desmoglein 4 and nude mRNAs
DE69837274D1 (de) Verfahren zur verkapselung von nukleinsäuren in lipiddoppelschichten
JP2022522768A (ja) ポリリボヌクレオチド及びその化粧用の使用
KR20210027389A (ko) 공여자 폴리뉴클레오티드의 삽입에 의한 게놈 편집을 위한 조성물 및 방법
EP4253544A2 (fr) Arn messager modifié comprenant des éléments d'arn fonctionnels
WO1994023026A1 (fr) Oligonuclotides agrafes et semi-agrafes, procede de preparation et applications
Cazenave et al. Anti-messenger oligodeoxynucleotides: specific inhibition of rabbit β-globin synthesis in wheat germ extracts and Xenopus oocytes
EP3784258A1 (fr) Composition d'exosome artificiel et procédés associés
CN106456542A (zh) 用于局部递送的适体
Woisard et al. Multiple folded conformations of a hammerhead ribozyme domain under cleavage conditions
Gaillard et al. Identity of the RNA-binding protein K of hnRNP particles with protein H16, a sequence-specific single strand DNAbinding protein
WO2001032220A1 (fr) Therapie genique pour traiter les maladies ischemiques diabetiques
KR101813560B1 (ko) 세포투과형 성장인자들의 피부 생리활성 피부외용제 조성물
WO2006036082A1 (fr) Produit cosmetique et procede de fabrication correspondant
RU2407509C2 (ru) Косметическое средство и способ его получения
KR20190137894A (ko) Igf-1r 억제용 p-에톡시 핵산
RU2766701C2 (ru) Антисмысловые олигонуклеотиды для snap25
ZAMECNIK Background of the antisense oligonucleotide approach to chemotherapy
EP1399570A2 (fr) Peptides destines a etre utilises en tant que facteurs de translocation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007112836

Country of ref document: RU

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase